Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK)
Crossref DOI link:
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Mueller, Ruediger B.
von Kempis, Johannes
Funding for this research was provided by:
Bristol-Myers-Squibb, Princeton, NJ, USA